| (Values in U.S. Thousands) | Sep, 2019 | Jun, 2019 | Mar, 2019 | Dec, 2018 | Sep, 2018 |
| Sales | 22,450 | 13,500 | 20,770 | 13,160 | 10,710 |
| Sales Growth | +66.30% | -35.00% | +57.83% | +22.88% | -57.48% |
| Net Income | -66,600 | -64,230 | -54,360 | -65,260 | -47,360 |
| Net Income Growth | -3.69% | -18.16% | +16.70% | -37.80% | -159.07% |
Spark Therap (ONCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Fiscal Year End Date: 12/31